BioSpace

Weighing the risks of CAR T in autoimmune disease as Kyverna nears market

Not a month after reports of three deaths in autoimmune trials for Novartis' CAR T cell therapy ignited a debate about the use of these treatments in nonfatal diseases, Kyverna Therapeutics reported data bolstering its case to bring to market the first CAR T for an autoimmune disease.

作者 BioSpace

1 分钟阅读
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market

有活动行业的新闻要分享吗?

提交新闻稿或信息,触达数千名活动行业专业人士。

联系我们→

更多Health Tech相关内容

相关洞察